格列齐特,gliclazide
1)gliclazide格列齐特
1.Preparation of gliclazide push-pull osmotic pump system;格列齐特推拉式渗透泵的制备
2.Optimization of Formula and Preparation Technology of Gliclazide Dispersible Tablets;格列齐特分散片处方及制备工艺研究
3.Formula and Preparation Technology of Gliclazide Controlled-release Tablets;格列齐特缓释片处方及工艺研究
英文短句/例句

1.Clinical observation of type 2 diabetes treatment by use of gliclazide modified release tablets instead of Gliclazide Ordinary Tablets格列齐特普通片改为格列齐特缓释片治疗2型糠尿病的临床观察
2.Study on the Formulation and Quality of Gliclazide Sustained Release Tablet;格列齐特缓释片处方筛选及质量研究
3.To improve synthesis process of intermediate of Gliclazide格列齐特中间体氮杂双环的工艺改进
4.The Study of Gliclazide Oral Controlled (Sustained) Release Formulations;难溶性药物格列齐特口服控(缓)释制剂的研究
5.Study and Application of a Quantification Method for Determination of Gliclazide in Human Plasma by LC/MS/MS;测定血浆中格列齐特的分析方法研究及应用
6.Design and Evaluation of Gel Matrix Sustained Release Tablet of Gliclazide;格列齐特凝胶骨架缓释片的设计与评价
7.On-line analysis with fiber-optical sensor on dissolution rate of glicalzide sustained-release tablets光纤传感在线监测格列齐特缓释片的释放度
8.RP-HPLC determination of the content and the related substances of Gliclazide Tablets(Ⅱ)RP-HPLC法测定格列齐特片(Ⅱ)的有关物质及含量
9.Preparation and Pharmacokinetics in Beagle Dogs of Gliclazide Osmotic Pump Controlled-release Tablets格列齐特渗透泵控释片的制备及犬体内药动学
10.Pharmacokinetics of gliclazide osmotic pump tablets in Beagle dogs格列齐特渗透泵片在Beagle犬体内的药动学
11.Preparation of gliclazide sustained-release tablets and influencing factors on its release格列齐特缓释片的制备及其释药因素考察
12.Clinical Epidemiological Study on Antihyperglycemic Efficacy Response to Gliclazide Treatment for Type 2 Diabetes;格列齐特治疗2型糖尿病疗效的临床流行病学研究
13.Studies on Bioequivalence and in Vitro/in Vivo Correlations of Gliclazide Sustained-release Tablets in Healthy Volunteers;格列齐特缓释片人体生物等效性及体内外相关性研究
14.Study on the Preparation of Hydroxypropylmethylcellulose Matrix Tablets Containing Gliclazide Complexed with Hydroxypropyl-β-cyclodextrin;格列齐特-羟丙基-β-环糊精包合物及缓释片的研究
15.Pharmacokinetics and Bioequivalence of Gliclazide Sustained-release Tablets in Healthy Volunteers after High Fat Diet格列齐特缓释片在健康人高脂饮食后的药动学及生物等效性
16.Determination of Gliclazide Tablets in Human Plasma by HPLC:Application to Bioequivalence and Pharmacokinetics Study高效液相色谱法研究人体内格列齐特片药动学和生物等效性
17.Gliclazide-modified-release on improving peripheral vascular function of patients with diabetic angiopathies格列齐特缓释片改善糖尿病周围血管病患者血管功能的临床研究
18.The Correlation between Primary Failure and Hypoglycemic Reaction after Treatment with Gliclazide in Type 2 Diabetes Mellitus and SUR1 Gene Polymorphism;格列齐特治疗2型糖尿病原发失效及低血糖反应与磺脲受体1基因多态性的相关性
相关短句/例句

Gliclazide Tablets格列齐特片
1.Determination the Content of Gliclazide in Gliclazide Tablets by HPLC;高效液相色谱法测定格列齐特片的含量
2.Preparation and release kinetics of gliclazide tablets;格列齐特片的制备及释药动力学
3.Determination of gliclazide and its related substances in gliclazide tablets by HPLC;HPLC分离测定格列齐特片及其有关物质
3)Gliclazide格列齐特片
1.Pharmacokinetics and bioequivalence study of Gliclazide tables in Chinese healthy volunteers;格列齐特片在健康人体内的药代动力学及生物等效性研究
2.Objective To study the relative bioavailability of gliclazide in healthy volunteers.目的 研究格列齐特片的健康人体药物动力学及相对生物利用度。
4)Gliclazide Sustained Release Tablets格列齐特缓释片
1.Compound Danshen Tablets Assisting Gliclazide Sustained Release Tablets and Acarbose Tablets for Type 2 Diabetes:Observation of Curative Effect;复方丹参片辅助格列齐特缓释片、阿卡波糖片治疗2型糖尿病疗效观察
2.Bioequivalence study of gliclazide sustained release tablets;格列齐特缓释片的人体生物等效性
3.Methods 120 patients,with type Ⅱ diabetes were randomly assigned to Control and treatment groups,the control group(n=60)receive Gliclazide Sustained Release Tablets plus Acarbose Tablets for 10 weeks,and treatment group(n=60)to receive Gliclazide Sustained Release Tablets + Acarbose Tablets in combination with Fufang Danshen Drop-pill for 10 weeks.方法选择120例2型糖尿病患者,随机平分为对照组和治疗组各60例,对照组服用格列齐特缓释片、阿卡波糖片;治疗组在对照组用西药格列齐特缓释片、阿卡糖片的基础上加服复方丹参滴丸,疗程10周。
5)Gliclazide Tablets(Ⅱ)格列齐特(Ⅱ)片
6)Gliclazide Modified Release Tablet格列齐特缓释片
1.The observation of treatment of Gliclazide Modified Release Tablet in Type 2 diabetic patients;格列齐特缓释片治疗2型糖尿病的疗效观察
延伸阅读

格列齐特【通用名称】格列齐特【其他名称】格列齐特 格列齐特 拼音名:Gelieqite 英文名:Gliclazide 书页号:2000年版二部-702 C15H21N3O3S 323.41 本品为1-(3-氮杂双环[3,3,0]辛基)-3-对甲苯磺酰脲。按干燥品计算,含C15H21N3 O3S不得少于98.5%。 【性状】 本品为白色结晶或结晶性粉末,无臭、无味。 本品在氯仿中溶解,在甲醇中略溶,在乙醇中微溶,在水中不溶。 熔点 本品的熔点(附录Ⅵ C)为162~166℃。 【鉴别】 (1)取本品少许,滴加吡啶后仅有微量未溶,再滴加硫酸铜试液5滴,振摇, 显蓝紫色。 (2)取本品,精密称定,加乙醇制成每1ml约含10μg的溶液,照分光光度法(附录Ⅳ A)测定,在228nm的波长处有最大吸收。 (3)本品的红外光吸收图谱应与对照品的图谱一致。 【检查】 有关物质 取本品,加氯仿制成每1ml中含20mg的溶液,作为供试品溶液, 精密量取适量,加氯仿稀释成每1ml中含0.2mg的溶液,作为对照溶液。照薄层色谱法( 附录Ⅴ B)试验,吸取上述两种溶液各10μl,分别点于同一硅胶G薄层板上,以醋酸乙 酯-氯仿-甲醇(6:4:2)为展开剂,展开后,晾干,喷以茚三酮-氯化亚锡溶液(取茚三 酮0.4g,氯化亚锡40mg,加乙醇20ml振摇使溶解,用时新配),晾干后,再喷一次,在 120℃干燥30分钟。供试品溶液如显杂质斑点,与对照溶液的主斑点比较,不得更深。 干燥失重 取本品,在105℃干燥至恒重,减失重量不得过1.0%(附录Ⅷ L)。 炽灼残渣 不得过0.1%(附录Ⅷ N)。 重金属 取炽灼残渣项下遗留的残渣,依法检查(附录Ⅷ H第二法),含重金属不得 过百万分之十。 【含量测定】 取本品约0.2g,精密称定,加冰醋酸50ml溶解后,照电位滴定法(附录Ⅶ A),用高氯酸滴定液(0.1mol/L)滴定,并将滴定的结果用空白试验校正。每1ml高氯酸液(0.1m ol/L)相当于32.34mg的C15H21N3O3S。 【类别】 降血糖药。 【贮藏】 遮光,密封保存。 【制剂】 格列齐特片(Ⅱ)